Prescription drug · NDA AUTHORIZED GENERIC
Sucralfate NDC 59762-0401
Sucralfate 1 g/1 · Tablet · Oral · Mylan Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 59762-0401-1 | 59762040101 | 100 TABLET in 1 BOTTLE (59762-0401-1)Marketed from Sep 25, 2017 | |
| 59762-0401-5 | 59762040105 | 500 TABLET in 1 BOTTLE (59762-0401-5)Marketed from Sep 25, 2017 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Sucralfate
- Generic name (nonproprietary)
- sucralfate
- Active ingredients
- Sucralfate — 1 g/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Mylan Pharmaceuticals, Inc.
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 018333
- Marketing start
- Listing expires
- Other FDA classes
- Organometallic Compounds (Chemical structure)
- Identifiers
- Product ID 59762-0401_311db6f8-1bc9-46af-a866-d7ad4d8193dcSPL ID 311db6f8-1bc9-46af-a866-d7ad4d8193dcSPL set ID ae58c382-c1cf-4ebf-9c97-bdff0682df8bRxCUI 314234UNII XX73205DH5UPC 0359762040114, 0041200002760
- Pharmacologic class
- Aluminum Complex
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N459762040101followed by a unit qualifier and the quantityPackage 59762-0401-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Sucralfate is indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 018333
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Advanced Rx Pharmacy of Tennessee, LLC | 80425-0213 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Northwind Health Company, LLC | 51655-475 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Aphena Pharma Solutions - Tennessee, LLC | 71610-017 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Bryant Ranch Prepack | 71335-2637 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Preferred Pharmaceuticals Inc. | 68788-8316 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Advanced Rx Pharmacy of Tennessee, LLC | 80425-0377 |
| Carafatesucralfate | Sucralfate 1 g/1 | TabletOral | Allergan, Inc. | 58914-171 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | A-S Medication Solutions | 50090-5287 |